SOURCE: Research and Markets

Research and Markets

February 10, 2016 04:50 ET

Oncology Pathways in the US -- Friend or Foe for Pharma

DUBLIN, IRELAND--(Marketwired - February 10, 2016) -  Research and Markets ( has announced the addition of the "Oncology Pathways in the US - Friend or Foe for Pharma?" report to their offering.

The costs of treating cancer in the US are spiralling upward, and payers have taken notice. This report takes a detailed look at the growing focus on value and quality that is driving greater use of clinical pathways. This great piece of analysis will allow you to formulate successful strategies that allow you to enter this market, taking all factors into consideration.

Key Topics Covered:

  • Detailed analysis of the current uses of oncology pathways including third party vendors' business models, payer adoption and physicians' incentives
  • An overview of the impact of oncology pathways on oncology care and costs so far
  • A discussion of the likely impact of oncology pathways on the oncology drug market and pharma's market access strategies

Questions Answered:

  • Who is developing and using oncology clinical pathways?
  • What impact have oncology pathways had on the oncology drug use so far?
  • What strategies do pharmaceutical companies need to implement to mitigate the potential negative impact of oncology pathways on their oncology products or maximize opportunities?

Report Structure:

1. Executive Summary

2. Management of Oncology Costs

3. Oncology Clinical Pathway Programs and Developers

4. The Impact of Pathways on Oncology

5. Oncology Pathways and Pharma

6. Future of Oncology Pathways

For more information visit

Image Available:

Contact Information

    Research and Markets
    Laura Wood
    Senior Manager
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    U.S. Fax: 646-607-1907
    Fax (outside U.S.): +353-1-481-1716